1
|
Maitha GM, Kikuvi G, Wanzala P, Kirui F. Influence of hepatitis B virus co-infection on virological and immunological response to antiretroviral treatment among HIV patients attending comprehensive care clinics in Makueni County, Kenya. Pan Afr Med J 2021; 38:103. [PMID: 33889269 PMCID: PMC8035691 DOI: 10.11604/pamj.2021.38.103.25793] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 01/23/2021] [Indexed: 11/30/2022] Open
Abstract
Introduction the effect of hepatitis B virus (HBV) infection on the natural history of human immunodeficiency virus (HIV) disease remains uncertain. Therefore, this study was conducted to determine the association of HBV co-infections with CD4 count and viral load levels in response to antiretroviral treatment among HIV patients attending comprehensive care clinics in Makueni County (Kenya). Methods this was a prospective case-control study among patients seeking HIV services in three hospitals of Makueni County (Kenya). Newly diagnosed HIV mono-infected patients (controls) and HIV/HBV co-infected (cases), 18 years and above who had not started antiretrovirals (ARVs) participated. A total of 258 patients gave informed consent and participated. HIV mono-infected (controls) produced 129 while HIV/HBV (cases) gave 129 participants. P-values ≤ 0.05 were considered significant. Results the majority (164, 63%) of the study participants were females for both arms of the study. The mean age of the participants was 31±0.402 years and majority of them were between the age of 26-30years old. At the beginning and end of the study the mean viral load for HIV/HBV co-infected individuals was (30169 and 1731) copies/ml while that of CD4 count was (327 and 459) cells/ul, and that of HIV mono-infected was (21860 and 1689) copies/ml and CD4 count of (421 and 437) cells/ul respectively. After enrolling them into antiretroviral therapy (ART) treatment and after six months of follow-up there was significant drop in viral load and significant increase in CD4 count for both groups at p<0.001 using logistic regression. Conclusion HIV patients co-infected with hepatitis B virus had high viral load and low CD4 count compared to HIV monoinfected patients however with introduction of ARVs there was improvement in both groups with the highest noticed among the HIV/HBV co-infected patients.
Collapse
Affiliation(s)
- Geoffrey Mutisya Maitha
- School of Public Health, Jomo Kenyatta University of Science Agriculture and Technology, Nairobi, Kenya
| | - Gideon Kikuvi
- School of Public Health, Jomo Kenyatta University of Science Agriculture and Technology, Nairobi, Kenya
| | | | | |
Collapse
|
2
|
Sereti I, Sheikh V, Shaffer D, Phanuphak N, Gabriel E, Wang J, Nason MC, Roby G, Ngeno H, Kirui F, Pau A, Mican JM, Rupert A, Bishop R, Agan B, Chomchey N, Teeratakulpisarn N, Tansuphaswadikul S, Langat D, Kosgei J, French M, Ananworanich J, Sawe F. Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia. Clin Infect Dis 2020; 71:652-660. [PMID: 31504347 PMCID: PMC7384325 DOI: 10.1093/cid/ciz877] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 09/03/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Patients living with human immunodeficiency virus (PLWH) with low CD4 counts are at high risk for immune reconstitution inflammatory syndrome (IRIS) and death at antiretroviral therapy (ART) initiation. METHODS We investigated the clinical impact of IRIS in PLWH and CD4 counts <100 cells/μL starting ART in an international, prospective study in the United States, Thailand, and Kenya. An independent review committee adjudicated IRIS events. We assessed associations between baseline biomarkers, IRIS, immune recovery at week 48, and death by week 48 with Cox models. RESULTS We enrolled 506 participants (39.3% were women). Median age was 37 years, and CD4 count was 29 cells/μL. Within 6 months of ART, 97 (19.2%) participants developed IRIS and 31 (6.5%) died. Participants with lower hemoglobin at baseline were at higher IRIS risk (hazard ratio [HR], 1.2; P = .004). IRIS was independently associated with increased risk of death after adjustment for known risk factors (HR, 3.2; P = .031). Being female (P = .004) and having a lower body mass index (BMI; P = .003), higher white blood cell count (P = .005), and higher D-dimer levels (P = .044) were also significantly associated with increased risk of death. Decision-tree analysis identified hemoglobin <8.5 g/dL as predictive of IRIS and C-reactive protein (CRP) >106 μg/mL and BMI <15.6 kg/m2 as predictive of death. CONCLUSIONS For PLWH with severe immunosuppression initiating ART, baseline low BMI and hemoglobin and high CRP and D-dimer levels may be clinically useful predictors of IRIS and death risk.
Collapse
Affiliation(s)
- Irini Sereti
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Virginia Sheikh
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Douglas Shaffer
- Walter Reed Army Institute of Research/US Army Medical Research Directorate–Africa, Nairobi, Kenya
- Walter Reed Army Institute of Research, US Military Human Immunodeficiency Virus Research Program, Silver Spring, Maryland, USA
| | - Nittaya Phanuphak
- South East Asia Research Collaboration with Hawaii, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
| | - Erin Gabriel
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Jing Wang
- Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, National Cancer Institute Campus at Frederick, Maryland, USA
| | - Martha C Nason
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Gregg Roby
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Hellen Ngeno
- Walter Reed Army Institute of Research/US Army Medical Research Directorate–Africa, Nairobi, Kenya
| | - Fredrick Kirui
- Kenya Medical Research Institute/US Army Medical Research Directorate–Africa–Kenya/ Henry Jackson Foundation Medical Research International, Kericho Clinical Research Center, Kenya
| | - Alice Pau
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Joann M Mican
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Adam Rupert
- Applied and Developmental Research Directorate, AIDS Monitoring Laboratory, Leidos Biomedical Research, Inc, Frederick, Maryland, USA
| | - Rachel Bishop
- National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Brian Agan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA
| | - Nitiya Chomchey
- South East Asia Research Collaboration with Hawaii, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
| | - Nipat Teeratakulpisarn
- South East Asia Research Collaboration with Hawaii, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
| | | | - Deborah Langat
- Kenya Medical Research Institute/US Army Medical Research Directorate–Africa–Kenya/ Henry Jackson Foundation Medical Research International, Kericho Clinical Research Center, Kenya
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA
| | - Josphat Kosgei
- Kenya Medical Research Institute/US Army Medical Research Directorate–Africa–Kenya/ Henry Jackson Foundation Medical Research International, Kericho Clinical Research Center, Kenya
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA
| | - Martyn French
- University of Western Australia, Medical School and School of Biomedical Sciences, Nedlands, Australia
| | - Jintanat Ananworanich
- South East Asia Research Collaboration with Hawaii, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA
- US Military Human Immunodeficiency Virus Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
- Department of Global Health, Amsterdam Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Fredrick Sawe
- Kenya Medical Research Institute/US Army Medical Research Directorate–Africa–Kenya/ Henry Jackson Foundation Medical Research International, Kericho Clinical Research Center, Kenya
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA
| |
Collapse
|
3
|
Oyando R, Njoroge M, Nguhiu P, Sigilai A, Kirui F, Mbui J, Bukania Z, Obala A, Munge K, Etyang A, Barasa E. Patient costs of diabetes mellitus care in public health care facilities in Kenya. Int J Health Plann Manage 2019; 35:290-308. [PMID: 31621953 PMCID: PMC7043382 DOI: 10.1002/hpm.2905] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Accepted: 09/05/2019] [Indexed: 11/08/2022] Open
Abstract
OBJECTIVE To estimate the direct and indirect costs of diabetes mellitus care at five public health facilities in Kenya. METHODS We conducted a cross-sectional study in two counties where diabetes patients aged 18 years and above were interviewed. Data on care-seeking costs were obtained from 163 patients seeking diabetes care at five public facilities using the cost-of-illness approach. Medicines and user charges were classified as direct health care costs while expenses on transport, food, and accommodation were classified as direct non-health care costs. Productivity losses due to diabetes were classified as indirect costs. We computed annual direct and indirect costs borne by these patients. RESULTS More than half (57.7%) of sampled patients had hypertension comorbidity. Overall, the mean annual direct patient cost was KES 53 907 (95% CI, 43 625.4-64 188.6) (US$ 528.5 [95% CI, 427.7-629.3]). Medicines accounted for 52.4%, transport 22.6%, user charges 17.5%, and food 7.5% of total direct costs. Overall mean annual indirect cost was KES 23 174 (95% CI, 20 910-25 438.8) (US$ 227.2 [95% CI, 205-249.4]). Patients reporting hypertension comorbidity incurred higher costs compared with diabetes-only patients. The incidence of catastrophic costs was 63.1% (95% CI, 55.7-70.7) and increased to 75.4% (95% CI, 68.3-82.1) when transport costs were included. CONCLUSION There are substantial direct and indirect costs borne by diabetic patients in seeking care from public facilities in Kenya. High incidence of catastrophic costs suggests diabetes services are unaffordable to majority of diabetic patients and illustrate the urgent need to improve financial risk protection to ensure access to care.
Collapse
Affiliation(s)
- Robinson Oyando
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Martin Njoroge
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.,Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Peter Nguhiu
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Antipa Sigilai
- Centre for Geographic Medicine Research, Kenya Medical Research Institute, KiIifi, Kenya
| | - Fredrick Kirui
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Jane Mbui
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Zipporah Bukania
- Centre for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Andrew Obala
- Medical Microbiology, Moi University, Eldoret, Kenya
| | - Kenneth Munge
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Anthony Etyang
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.,Centre for Geographic Medicine Research, Kenya Medical Research Institute, KiIifi, Kenya
| | - Edwine Barasa
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.,Nuffield Department of Medicine, University of Oxford, Oxford, UK
| |
Collapse
|
4
|
Etyang AO, Sigilai A, Odipo E, Oyando R, Ong'ayo G, Muthami L, Munge K, Kirui F, Mbui J, Bukania Z, Mwai J, Obala A, Barasa E. Diagnostic Accuracy of Unattended Automated Office Blood Pressure Measurement in Screening for Hypertension in Kenya. Hypertension 2019; 74:1490-1498. [PMID: 31587589 PMCID: PMC7069390 DOI: 10.1161/hypertensionaha.119.13574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Supplemental Digital Content is available in the text. Despite increasing adoption of unattended automated office blood pressure (uAOBP) measurement for determining clinic blood pressure (BP), its diagnostic performance in screening for hypertension in low-income settings has not been determined. We determined the validity of uAOBP in screening for hypertension, using 24-hour ambulatory BP monitoring as the reference standard. We studied a random population sample of 982 Kenyan adults; mean age, 42 years; 60% women; 2% with diabetes mellitus; none taking antihypertensive medications. We calculated sensitivity using 3 different screen positivity cutoffs (≥130/80, ≥135/85, and ≥140/90 mm Hg) and other measures of validity/agreement. Mean 24-hour ambulatory BP monitoring systolic BP was similar to mean uAOBP systolic BP (mean difference, 0.6 mm Hg; 95% CI, −0.6 to 1.9), but the 95% limits of agreement were wide (−39 to 40 mm Hg). Overall discriminatory accuracy of uAOBP was the same (area under receiver operating characteristic curves, 0.66–0.68; 95% CI range, 0.64–0.71) irrespective of uAOBP cutoffs used. Sensitivity of uAOBP displayed an inverse association (P<0.001) with the cutoff selected, progressively decreasing from 67% (95% CI, 62–72) when using a cutoff of ≥130/80 mm Hg to 55% (95% CI, 49–60) at ≥135/85 mm Hg to 44% (95% CI, 39–49) at ≥140/90 mm Hg. Diagnostic performance was significantly better (P<0.001) in overweight and obese individuals (body mass index, >25 kg/m2). No differences in results were present in other subanalyses. uAOBP misclassifies significant proportions of individuals undergoing screening for hypertension in Kenya. Additional studies on how to improve screening strategies in this setting are needed.
Collapse
Affiliation(s)
- Anthony O Etyang
- From the Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme (A.O.E., A.S., E.O., G.O.)
| | - Antipa Sigilai
- From the Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme (A.O.E., A.S., E.O., G.O.)
| | - Emily Odipo
- From the Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme (A.O.E., A.S., E.O., G.O.)
| | - Robinson Oyando
- Health Economics Research Unit, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya (R.O., K.M., E.B.)
| | - Gerald Ong'ayo
- From the Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme (A.O.E., A.S., E.O., G.O.)
| | - Lawrence Muthami
- Centre for Public Health Research (L.M., Z.B., J.M.), Kenya Medical Research Institute, Nairobi
| | - Kenneth Munge
- Health Economics Research Unit, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya (R.O., K.M., E.B.)
| | - Fredrick Kirui
- Centre for Clinical Research (F.K., J.M.), Kenya Medical Research Institute, Nairobi
| | - Jane Mbui
- Centre for Clinical Research (F.K., J.M.), Kenya Medical Research Institute, Nairobi
| | - Zipporah Bukania
- Centre for Public Health Research (L.M., Z.B., J.M.), Kenya Medical Research Institute, Nairobi
| | - Judy Mwai
- Centre for Public Health Research (L.M., Z.B., J.M.), Kenya Medical Research Institute, Nairobi
| | | | - Edwine Barasa
- Health Economics Research Unit, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya (R.O., K.M., E.B.)
| |
Collapse
|
5
|
Oyando R, Njoroge M, Nguhiu P, Kirui F, Mbui J, Sigilai A, Bukania Z, Obala A, Munge K, Etyang A, Barasa E. Patient costs of hypertension care in public health care facilities in Kenya. Int J Health Plann Manage 2019; 34:e1166-e1178. [PMID: 30762904 PMCID: PMC6618067 DOI: 10.1002/hpm.2752] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 01/16/2019] [Indexed: 11/09/2022] Open
Abstract
Background Hypertension in low‐ and middle‐income countries, including Kenya, is of economic importance due to its increasing prevalence and its potential to present an economic burden to households. In this study, we examined the patient costs associated with obtaining care for hypertension in public health care facilities in Kenya. Methods We conducted a cross‐sectional study among adult respondents above 18 years of age, with at least 6 months of treatment in two counties. A total of 212 patients seeking hypertension care at five public facilities were interviewed, and information on care seeking and the associated costs was obtained. We computed both annual direct and indirect costs borne by these patients. Results Overall, the mean annual direct cost to patients was US$ 304.8 (95% CI, 235.7‐374.0). Medicines (mean annual cost, US$ 168.9; 95% CI, 132.5‐205.4), transport (mean annual cost, US$ 126.7; 95% CI, 77.6‐175.9), and user charges (mean annual cost, US$ 57.7; 95% CI, 43.7‐71.6) were the highest direct cost categories. Overall mean annual indirect cost was US$ 171.7 (95% CI, 152.8‐190.5). The incidence of catastrophic health care costs was 43.3% (95% CI, 36.8‐50.2) and increased to 59.0% (95% CI, 52.2‐65.4) when transport costs were included. Conclusions Hypertensive patients incur substantial direct and indirect costs. High rates of catastrophic costs illustrate the urgency of improving financial risk protection for these patients and strengthening primary care to ensure affordability of hypertension care.
Collapse
Affiliation(s)
- Robinson Oyando
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Martin Njoroge
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Peter Nguhiu
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Fredrick Kirui
- Clinical Unit, KEMRI Centre for Clinical Research, Nairobi, Kenya
| | - Jane Mbui
- Clinical Unit, KEMRI Centre for Clinical Research, Nairobi, Kenya
| | - Antipa Sigilai
- Epidemiology and Demography, KEMRI Centre for Geographic Medicine Research, Coast, Kilifi, Kenya
| | - Zipporah Bukania
- Public health nutrition, maternal and child health unit, KEMRI Centre for Public Health Research, Nairobi, Kenya
| | - Andrew Obala
- Medical Microbiology and Parasitology, Moi University, Eldoret, Kenya
| | - Kenneth Munge
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Anthony Etyang
- Epidemiology and Demography, KEMRI Centre for Geographic Medicine Research, Coast, Kilifi, Kenya
| | - Edwine Barasa
- Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.,Nuffield Department of Medicine, University of Oxford, Oxford, UK
| |
Collapse
|
6
|
Bisson GP, Ramchandani R, Miyahara S, Mngqibisa R, Matoga M, Ngongondo M, Samaneka W, Koech L, Naidoo K, Rassool M, Kirui F, Banda P, Mave V, Kadam D, Leger P, Henostroza G, Manabe YC, Bao J, Kumwenda J, Gupta A, Hosseinipour MC. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS 2017; 31:2217-2225. [PMID: 28742529 PMCID: PMC5633516 DOI: 10.1097/qad.0000000000001606] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
BACKGROUND Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear. METHODS We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4 T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4 T-cell response and new opportunistic infections. RESULTS Of 850 enrolled, the median pre-ART CD4 T-cell count was 18 cells/μl and 67 (7.9%) died. Baseline risk factors for death included lymphadenopathy, lower CD4 T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4 T-cell count and viral load for those who died (n = 43) vs. survived were 26 vs. 56 cells/μl and -2.7 vs. -2.7 log10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4 T-cell count was associated with a 20% increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01-1.42, P = .038). CONCLUSION Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.
Collapse
Affiliation(s)
- Gregory P. Bisson
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States
| | | | - Sachiko Miyahara
- Harvard T.H. Chan School of Public Health, Boston, United States
| | - Rosie Mngqibisa
- Durban International CRS, Durban University of Technology, Durban, South Africa
| | | | | | | | - Lucy Koech
- Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
| | - Kogieleum Naidoo
- South African MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit
| | - Mohammed Rassool
- Clinical HIV Research Unit, Department of Medicine, University of Witwatersrand, Johannesburg, South Africa
| | | | | | - Vidya Mave
- BJ Medical College-Johns Hopkins Clinical Trials Unit, Pune, India
| | - Dileep Kadam
- BJ Medical College-Johns Hopkins Clinical Trials Unit, Pune, India
| | | | | | - Yukari C. Manabe
- Johns Hopkins University School of Medicine, Baltimore, United States
| | - Jing Bao
- HJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases, Bethesda, United States
| | | | - Amita Gupta
- Johns Hopkins University School of Medicine, Baltimore, United States
| | - Mina C. Hosseinipour
- UNC Project, Lilongwe, Malawi
- University of North Carolina School of Medicine, Chapel Hill, United States
| | | |
Collapse
|
7
|
Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 2010; 4:e709. [PMID: 21049059 PMCID: PMC2964287 DOI: 10.1371/journal.pntd.0000709] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2009] [Accepted: 04/21/2010] [Indexed: 12/03/2022] Open
Abstract
Background Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed. Paromomycin was shown to be an efficacious first-line treatment with low toxicity in India. Methods This was a 3-arm multicentre, open-label, randomized, controlled clinical trial to compare three treatment regimens for VL in East Africa: paromomycin sulphate (PM) at 15 mg/kg/day for 21 days versus sodium stibogluconate (SSG) at 20 mg/kg/day for 30 days; and the combination of both dose regimens for 17 days. The primary efficacy endpoint was cure based on parasite-free tissue aspirates taken 6 months after treatment. Findings Overall, 135 patients per arm were enrolled at five centres in Sudan (2 sites), Kenya (1) and Ethiopia (2), when the PM arm had to be discontinued due to poor efficacy. The trial has continued with the higher dose of PM as well as the combination of PM and SSG arms. These results will be reported later. Baseline patient characteristics were similar among treatment arms. The overall cure with PM was significantly inferior to that with SSG (63.8% versus 92.2%; difference 28.5%, 95%CI 18.8% to 38.8%, p<0.001). The efficacy of PM varied among centres and was significantly lower in Sudan (14.3% and 46.7%) than in Kenya (80.0%) and Ethiopia (75.0% and 96.6%). No major safety issues with PM were identified. Conclusion The efficacy of PM at 15 mg/kg/day for 21 days was inadequate, particularly in Sudan. The efficacy of higher doses and the combination treatment warrant further studies. Visceral leishmaniasis (VL) is a fatal parasitic disease with 500,000 new cases each year according to WHO estimates. New and better treatment options are urgently needed in disease endemic areas due to the long courses, toxicity and development of resistance to current treatments. Recently, the antibiotic paromomycin was tested and registered in India to treat this disease. The current study describes a clinical trial to test the effectiveness of injectable paromomycin, either alone or in combination with the standard drug sodium stibogluconate in three East African countries—Sudan, Kenya and Ethiopia. The study showed that at the same paromomycin dose that was successfully used and registered in India, a far poorer outcome was obtained, particularly in Sudan, suggesting that there are either differences in the patients ability to respond to the drug or in the susceptibility of parasites in East Africa compared with those in India. However, no major safety concerns were noted with the treatment. Further research was initiated to see if a higher dose of paromomycin would perform better, especially in Sudan. The results of this and the performance of the combination arm will be reported later. Our study highlights the importance of considering geographical differences to treatment responses.
Collapse
Affiliation(s)
- Asrat Hailu
- Addis Ababa University, Addis Ababa, Ethiopia
| | - Ahmed Musa
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
| | - Monique Wasunna
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
- * E-mail:
| | - Manica Balasegaram
- Medecins Sans Frontieres-Holland, Amsterdam, The Netherlands
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | | | - Getahun Mengistu
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
| | | | | | - Teklu Weldegebreal
- Arba Minch Hospital, Regional Health Bureau of SNNP state, Arba Minch, Ethiopia
| | - Samson Tesfaye
- Arba Minch Hospital, Regional Health Bureau of SNNP state, Arba Minch, Ethiopia
| | | | - Eltahir Khalil
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
| | - Osama Ahmed
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
| | | | - Ahmed El-Hassan
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
| | - Muzamil Raheem
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
| | - Marius Mueller
- Medecins Sans Frontieres-Holland, Amsterdam, The Netherlands
| | - Yousif Koummuki
- Medecins Sans Frontieres-Holland, Amsterdam, The Netherlands
| | - Juma Rashid
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Jane Mbui
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Geoffrey Mucee
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Simon Njoroge
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Veronica Manduku
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Alice Musibi
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Geoffrey Mutuma
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Fredrick Kirui
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Hudson Lodenyo
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Dedan Mutea
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - George Kirigi
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Tansy Edwards
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Peter Smith
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Lawrence Muthami
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Catherine Royce
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | - Sally Ellis
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | - Moses Alobo
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | - Raymond Omollo
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | - Josephine Kesusu
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Rhoda Owiti
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - John Kinuthia
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | | |
Collapse
|